Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans
Author:
Affiliation:
1. Egret Pharma (Shanghai) Ltd, Shanghai, China;
2. Translational Medicine Group, Massachusetts General Hospital, Boston, MA, USA;
3. Molecular Medicine Research Institute, Sunnyvale, CA, USA
Publisher
Informa UK Limited
Subject
Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/00498254.2019.1654634
Reference17 articles.
1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
2. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD
3. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
4. A 96‐week, multinational, randomized, double‐blind, parallel‐group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus;Medicinal Chemistry Research;2024-07-10
2. Bexagliflozin in type 2 diabetes: a profile of its use;Drugs & Therapy Perspectives;2024-07
3. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial;Journal of Diabetes;2024-04
4. Meta‐analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin;Diabetes, Obesity and Metabolism;2023-12-27
5. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis;Expert Opinion on Pharmacotherapy;2023-10-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3